Delirium Clinical Trials

Find Delirium Clinical Trials Near You

VR for ICU Delirium Prevention

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to evaluate whether daily exposure to immersive virtual reality (VR) can reduce the incidence of delirium in high-risk, non-intubated ICU patients. Participants will be randomized to either standard ICU care or standard care plus once-daily 15-minute VR sessions consisting of calming natural scenes, guided meditation, and music. The study population includes adult surgical ICU patients at Cedars-Sinai who are CAM-ICU negative at enrollment and possess at least one established risk factor for delirium. Outcomes will include the incidence and duration of delirium, ICU and hospital length of stay, feasibility of the VR intervention, and the frequency of adverse events. By targeting a high-risk population with an innovative non-pharmacologic therapy, this trial aims to generate data to support integration of VR into ICU delirium prevention protocols.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Individuals who are currently admitted to the SICU at Cedars-Sinai Medical Center

• Expected ICU stay \>48 hours

• Richmond Agitation Sedation Scale (RASS) score between -1 to +2.

• CAM-ICU negative

• 1≤ risk factor for delirium (Age ≥ 65 years old, history of cognitive impairment, sepsis, Sequential Organ Failure Assessment (SOFA) score \>5, history of alcohol or benzodiazepine abuse, recent major surgery)

Locations
United States
California
Cedars Sinai Medical Center
RECRUITING
Los Angeles
Contact Information
Primary
Devon S Callahan, MD
devon.callahan@cshs.org
310-423-2402
Time Frame
Start Date: 2026-03-10
Estimated Completion Date: 2028-04
Participants
Target number of participants: 822
Treatments
No_intervention: Standard ICU delirium prevention
Experimental: Study ICU Delirium Prevention and VR treatment
Related Therapeutic Areas
Sponsors
Leads: Cedars-Sinai Medical Center

This content was sourced from clinicaltrials.gov